📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. (2012)

First Author: Corrie PG

Attributed to: Hub in Trials Methodology Research (MRC Biostatistics Unit, Cambridge) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2012.318

PubMed Identifier: 22814578

Publication URI: http://europepmc.org/abstract/MED/22814578

Type: Journal Article/Review

Volume: 107

Parent Publication: British journal of cancer

Issue: 4

ISSN: 0007-0920